The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.20
Bid: 5.52
Ask: 7.00
Change: 0.08 (1.31%)
Spread: 1.48 (26.812%)
Open: 6.20
High: 6.20
Low: 6.20
Prev. Close: 6.12
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Synairgen raises 2.5m pounds from placing

Wed, 18th Jul 2012 09:39

Synairgen, a Southampton-based research firm, has placed around 5.56m shares at 45p each, enabling the firm to progress with its primary programme following the successful clinical trial results of an asthma treatment product. The placing has raised £2.5m before expenses. In a related transaction, Lansdowne Partners and IP Group are subscribing for 1.1m and 1.01m placing shares respectively, giving them an interest in 15m and 13.7m, representing 20.00% and 18.24% of the company's enlarged issued share capital, respectively. The proceeds will be used to further develop its asthma treatment programme, which, following recent trials, has confirmed clinically important and statistically significant differences in favour of inhaled interferon beta as compared to placebo for patients with "difficult to treat" asthma (estimated to be 10% -20% in the adult asthma population) across a number of recognised asthma trial endpoints such as asthma symptoms, lung function, and exacerbations. As a result of the positive data, Synairgen believes that it is in a strong position to partner the programme to progress inhaled IFN-beta for multiple indications.As part of this process, and in order to ensure that Synairgen achieves the maximum value in any potential partnership deal, the company now intends to use the proceeds of the placing to bring forward a biomarker programme to support the development of inhaled IFN-beta and to further characterise the responder population. Funds will also be used to progress the company's drug development plan to maintain momentum on the programme and to be ready to commence the next planned studies with a partner in asthma and COPD in 2013.In addition, some of the funds will be used to initiate the firm's interaction with the US government in order to position it ahead of an exploration into the potential of inhaled IFN-beta as a broad spectrum antiviral for severe viral lung infections. Remaining funds will be used for working capital requirements. The shares will be admitted onto AIM on July 23rd. The share price fell 8.91% to 46p by 09:49.NR
More News
19 Apr 2012 10:22

Synairgen no wheeze as asthma drug trial boosts shares

Southampton based research firm, Synairgen, has rocketed in morning trading after announcing results for a treatment which could protect asthmatics from respiratory virus infections. The drug, called SNG001, stops infections like the common cold spreading to patients' lungs, which is often the caus

Read more
29 Jan 2011 14:04

Takeover targets named

Hold on tight, a wave of patent expiries and generic competition could spark another round of consolidation in the pharma and medical devices sector this year. Billions of dollars have been spent on takeovers or pumped into new issues in recent months as confidence in the recovery grows and cash-ri

Read more
29 Jul 2010 12:51

Small caps round-up: Plantic Technologies, Acal, Anglesey

Shares in Plantic Technologies soared more than 50% after the biodegradeable plastics outfit agreed an 8p per share offer from a company controlled by Gordon Merchant, one of its directors. Acal, which provides technology products and services across Europe and South Africa, said underlying sales

Read more
29 Jul 2010 07:56

Synairgen FY Net Loss GBP2.6M Vs Loss GBP2.5M

LONDON (Dow Jones)--Synairgen PLC (SNG.LN), a respiratory drug discovery and development company with a particular focus on viral defense, Thursday reported a full year net loss of GBP2.6 million, compared with a loss of GBP2.5 million the previous year. MAIN FACTS: -Research and development

Read more
17 May 2010 13:02

Small caps: Cove Energy, Synairgen, Wilmington...

PR specialist Freshwater cut the dividend as profits fell to £32,000 from £106,000 in the six months to end February. Revenues fell to £3.66m from £4.51m. "While the economic environment remains challenging, Freshwater is seeing greater stability and growth potential in most of its markets. Alongsi

Read more
6 May 2010 12:49

Small caps round-up: Griffin Mining, Energy XXI

Griffin Mining posted a rise in profits in the year to December 31 despite a slide in revenues following the collapse in metals prices in late 2008. The company, which operates the Caijiaying zinc-gold mine in China, posted a pre-tax profit of $7.2m, up from $7m in 2008, even as revenues fell to $2

Read more
9 Nov 2009 16:31

London close: Miners power Footsie gains

Mining stocks were at the vanguard of a strong advance from FTSE 100 as commodity prices were boosted by plans outlined by world leaders over the weekend to continue with stimulus measures. Kazakhmys, Fresnillo, Rio Tinto and Vedanta were some of the best performers in the mining sector. Mining g

Read more
9 Nov 2009 14:23

London afternoon: Cadbury rejects Kraft bid

After all the waiting and speculation, the formal bid for Cadbury from US group Kraft Foods proved a disappointment, but it has not dampened sentiment in a buoyant London market. Kraft formally announced a bid for Cadbury on the same terms as the indicative offer announced at the beginning of Septe

Read more
9 Nov 2009 08:42

Synairgen hails swine flu result

The share price of respiratory disease drug developer Synairgen more than doubled in early trading on Monday after positive developments for its inhaled interferon beta programme. Laboratory experiments confirmed the antiviral potency of IFN-beta against 2009 H1N1, better known as ‘swine flu’. The

Read more
27 May 2009 07:59

Small caps round-up: LonZim, Lees Foods, blinkx ...

Zimbabwe-focused investment company LonZim said it is well-placed to benefit from any upturn in the southern African country's economy after investing in several sectors in the six months to February 28. The company posted a pre-tax loss of £911,000 as it invested in telecoms, aviation and hotel se

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.